SATELLOS BIOSCIENCE
Satellos Bioscience is a regenerative medicine company formed in 2018 as a partnership among Dr. Michael Rudnicki, one of the country’s foremost stem cell scientists and CEO of the Stemcell Network of Canada, Bloom Burton & Co. – the nation’s largest healthcare investment bank -- and Mr. Frank Gleeson, a serial biotech entrepreneur and former healthcare VC. Satellos has recently completed a seed round of financing to pursue its unique approach of pharmacologically modulating stem cell polarity to stimulate in vivo tissue repair and regeneration. Our initial focus is muscle regeneration, a field in which Dr. Rudnicki is a world leader, with a lead program in Duchenne Muscular Dystrophy.
SATELLOS BIOSCIENCE
Industry:
Pharmaceutical
Founded:
2018-01-01
Address:
Toronto, Ontario, Canada
Country:
Canada
Website Url:
http://www.satellos.com
Total Employee:
1+
Status:
Active
Contact:
905-336-6128
Email Addresses:
[email protected]
Total Funding:
1000 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Content Delivery Network Font Awesome Wordpress Plugins
Similar Organizations
Advanced Cell Diagnostics
Advanced Cell Diagnostics is a molecular pathology company developing cell- and tissue-based diagnostic tests for personalized medicine.
Cyagen Biosciences
Cyagen Biosciences is an emerging and innovative biotechnology company.
LivWell Enlightened Health
LivWell Enlightened Health is a medical cannabis company producing and retailing multi-state cannabis.
Current Employees Featured
Founder
Investors List
Parent Project Muscular Dystrophy
Parent Project Muscular Dystrophy investment in Grant - Satellos Bioscience
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-17 | Satellos Bioscience Announces Appointment of J. Robert Hall as Vice-President, Finance and Administration |
Official Site Inspections
http://www.satellos.com Semrush global rank: 5.88 M Semrush visits lastest month: 1.41 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Satellos Bioscience"
About - Satellos
Satellos is exploring new pathways for medicines to improve the treatment of degenerative muscle diseases. Founded on breakthrough research in muscle stem cell biology, the …See details»
Satellos Bioscience - Crunchbase Company Profile
Satellos Bioscience is a private regenerative medicine company developing novel therapeutics that stimulate or restore muscle regeneration. The company's programs focus on developing an oral therapeutic drug for Duchenne …See details»
Satellos Bioscience Inc. - Investor Relations
Sep 5, 2024 Satellos is dedicated to developing life-improving medicines to treat degenerative muscle diseases and is building a pipeline of novel therapeutics to promote the body’s innate …See details»
Satellos Appoints Stephanie Brown to Board of Directors
Nov 14, 2024 Satellos Bioscience Inc. (TSX: MSCL) (OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a public biotech company developing new small molecule therapeutic …See details»
Satellos - Overview, News & Similar companies | ZoomInfo.com
Who is Satellos. Satellos was co-founded by biotechnology entrepreneurs Mr. Frank Gleeson and Dr. Michael Rudnicki PhD, FRS, OC to create new therapeutic treatments for degenerative …See details»
Satellos Bioscience Inc. | Newsfile
Jun 30, 2023 Satellos to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023. Toronto, Ontario--(Newsfile Corp. - September 20, 2023) - Satellos Bioscience Inc. …See details»
Satellos Bioscience Company Description - Stock Analysis
Dec 6, 2024 Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The …See details»
Satellos Receives Company of the Year Award from Life Sciences …
May 30, 2024 The LSO Awards are an important part of the organization’s goal to advocate for Ontario’s life sciences sector, by celebrating the individuals and companies behind its …See details»
Satellos Appoints Stephanie Brown to Board of Directors
Nov 14, 2024 Satellos Bioscience Inc., a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, …See details»
Satellos Recognized as a Top 50 TSX Venture Exchange Company
Feb 21, 2024 Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL), a public biotech company developing new small molecule therapeutic approaches to improve the …See details»
Satellos Bioscience Inc, MSCL:TOR profile - FT.com - Financial Times
Dec 20, 2024 Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve …See details»
Satellos Bioscience Inc. Opens the Market - Newswire
TORONTO, May 15, 2024 /CNW/ - Frank Gleeson Co-Founder and Chief Executive Officer, Satellos Bioscience Inc. (TSX: MSCL) ("Satellos" or the "Company"), and his team joined Dani …See details»
Satellos Announces Closing of US$40M Public Offering
Dec 20, 2024 Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic …See details»
Contact - Satellos
Please click on Patients, Partnering, Media, or General Info, to direct your message accordingly. Do not submit medical information in the form.See details»
Satellos Bioscience Inc. - Satellos Announces Pricing of US$40M ...
Dec 17, 2024 TORONTO--(BUSINESS WIRE)-- Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a public biotech company developing new small …See details»
Satellos Bioscience Inc. - Life Sciences Ontario Announces …
Jan 15, 2024 Leadership Award – Dr. Durhane Wong-Rieger, President and Chief Executive Officer, Canadian Organization for Rare Disorders (CORD) Company of the Year Award – …See details»
Stephanie Brown - Satellos
Prior to Santhera, she led the Rare Diseases business at Ipsen Biopharmaceutical North America, managing commercialization strategies and profit growth for in-line and launch brands. …See details»
Science - Satellos
Satellos was founded on decades of research in muscle biology that has uncovered new pathways to rethink how Duchenne muscular dystrophy is treated. Our Science Breakthrough …See details»
News - Satellos
Satellos Receives Rare Pediatric Disease Designation from the U.S. FDA for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy Press Release 05.28.2024 Satellos Announces …See details»